Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Covington
Mallinckrodt
McKesson
Harvard Business School
Farmers Insurance

Generated: September 23, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,457,154

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,457,154
Title:Injection device with an end of dose feedback mechanism
Abstract: An injection device with a dose delivering mechanism being adapted to provide a non-visual, e.g. audible and/or tactile, feedback signal when a set dose has been at least substantially injected. A first and a second part of the injection device are adapted to perform a relative rotational movement with respect to each other. The relative rotational movement causes at least two parts of the injection device to abut or engage, and this abutment or engagement causes the non-visual feedback signal to be generated. A very distinct and precise feedback is provided as compared to prior art axial solutions because the generation of the feedback signal is initiated by the relative rotational movement. Feedback signal may be generated by a change in a rotational velocity of at least one part, e.g. by changing the pitch of a threaded portion or by engaging a non-rotating part and a rotating part, thereby causing the non-rotating part to start rotating. May alternatively be generated by building up and releasing a tension. The injection device is suitable for injecting insulin.
Inventor(s): Moller; Claus Schmidt (Fredensborg, DK), Radmer; Bo (Hillerod, DK), Nielsen; Lars Ulrik (Virum, DK), Engaard; Christian Peter (Vejby, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:11/813,389
Patent Claim Types:
see list of patent claims
Delivery; Device; Use;

Drugs Protected by US Patent 9,457,154

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novo Nordisk Inc NORDITROPIN FLEXPRO somatropin recombinant INJECTABLE;INJECTION 021148-008 Mar 1, 2010 BX RX No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Novo Nordisk Inc NORDITROPIN FLEXPRO somatropin recombinant INJECTABLE;INJECTION 021148-009 Mar 1, 2010 BX RX No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Novo Nordisk Inc NORDITROPIN FLEXPRO somatropin recombinant INJECTABLE;INJECTION 021148-010 Mar 1, 2010 RX No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Novo Nordisk Inc NORDITROPIN FLEXPRO somatropin recombinant INJECTABLE;INJECTION 021148-011 Jan 23, 2015 RX No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Novo Nordisk Inc LEVEMIR FLEXTOUCH insulin detemir recombinant INJECTABLE;SUBCUTANEOUS 021536-005 Oct 31, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Novo Nordisk Inc NOVOLOG FLEXTOUCH insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 020986-005 Oct 31, 2013 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Novo FIASP FLEXTOUCH insulin aspart SOLUTION;SUBCUTANEOUS 208751-002 Sep 29, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,457,154

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
05075187Jan 25, 2005
PCT Information
PCT FiledJanuary 20, 2006PCT Application Number:PCT/EP2006/000486
PCT Publication Date:August 03, 2006PCT Publication Number: WO2006/079481

International Family Members for US Patent 9,457,154

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2006208606 ➤ Sign Up
Brazil PI0607012 ➤ Sign Up
Canada 2595323 ➤ Sign Up
China 101107032 ➤ Sign Up
Denmark 1877119 ➤ Sign Up
European Patent Office 1877119 ➤ Sign Up
Spain 2689536 ➤ Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Cipla
Teva
Argus Health
US Army
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.